ACAD
ACADIA PHARMACEUTICALS INC
NASDAQ · Healthcare · Biotechnology · US
$21.29
+3.50%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$21.18
From 52W high−30.36%
Volume2.18M
Market cap$3.67B
P/E (TTM)9.5x
P/S (TTM)3.2x
Div yield—
Key dataNov 4, 2026
Open
$21.18
From 52W high
−30.36%
Volume
2.18M
Market cap
$3.67B
ValuationView details →
P/E (Fwd)
22.8x
EV/EBITDA
24.0x
P/E (TTM)
9.5x
RSI (14)
50.0
MomentumView details →
1D Return
+3.50%
YTD Return
−21.46%
SummaryUpdated Jun 1, 2026
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is a San Diego-based biopharmaceutical company founded in 1993 that specializes in developing and commercializing treatments for central nervous system disorders. The company has evolved from a research-focused organization into a commercial-stage enterprise with two marketed products addressing rare neurological conditions. ACADIA went public in 2004 and has built its business around addressing unmet medical needs in neuropsychiatric and rare disease markets, with a particular focus on conditions affecting vulnerable patient populations including those with Parkinson's disease, Rett syndrome, and other neurological disorders.
Similar companies
Latest newsMore news →
Elizabeth H.Z. Thompson retired from her role as Acadia Pharmaceuticals' Executive Vice President and Head of Research and Development and became a consultant, effective October 23, 2026.12d agoAcadia Pharmaceuticals received a patent allowance for Daybue that extends U.S. protection to March 2041.36d agoThe United States Patent and Trademark Office issued a Notice of Allowance for Acadia Pharmaceuticals' U.S. Patent Application No. 17/590,496 covering weight-banded dosing of trofinetide, extending U.S. patent protections to March 2041.37d ago